Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Deals

Shanghai Kingstar Winning Secures $43.39 Million in Series C Financing for Digital Healthcare Solutions

Fineline Cube Apr 25, 2023

Shanghai Kingstar Winning Software Science and Technology Co., Ltd, a leading provider of digitalization risk...

Company Deals

Luzhu Biotech Prepares for HKD 433 Million IPO with Focus on Vaccines and Biologics

Fineline Cube Apr 25, 2023

Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is...

Company Drug

Gan & Lee Pharmaceuticals Receives Marketing Approval for Insulin Glargine in Bolivia

Fineline Cube Apr 25, 2023

Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced that it has...

Company Medical Device

Rainmed Medical’s caIMR System Receives NMPA Approval for Coronary Artery Function Measurement

Fineline Cube Apr 25, 2023

China-based Rainmed Medical Limited has announced that it has received market approval from the National...

Company

WuXi AppTec Reports 5.77% YOY Revenue Growth and 31.97% Increase in Net Profits for 2023Q1

Fineline Cube Apr 25, 2023

WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the...

Company Legal / IP

SMPA Suspends Procurement of Levornidazole by Warrant Pharmaceutical Over IP Concerns

Fineline Cube Apr 25, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification to suspend the procurement status...

Company Deals

Tot Biopharmaceutical Partners with Suzhou Smart Nuclide on Radioactive Drug Development

Fineline Cube Apr 25, 2023

China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Suzhou...

Company Drug

GSK’s Cervarix Receives Approval for Two-Dose Schedule in China for Ages 9 to 14

Fineline Cube Apr 24, 2023

The UK-based pharmaceutical giant GSK plc (NYSE: GSK) has announced the official market launch of...

Company Drug

Everest Medicines’ Nefecon for IgAN Approved for Clinical Use in Hainan

Fineline Cube Apr 24, 2023

China-based Everest Medicines (HKG: 1952) has announced that Nefecon (delayed-release budesonide), the first-in-disease treatment for...

Company Deals

Grand Pharmaceutical Group to Acquire Majority Stake in BlackSwan Vascular Inc. for $37.5 Million

Fineline Cube Apr 24, 2023

Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced plans to acquire...

Company Drug

Zelgen Biopharmaceuticals’ ZG2001 Receives US FDA Clinical Trial Approval for Pan-KRAS Inhibitor

Fineline Cube Apr 24, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Drug

Sichuan Biokin Pharmaceutical Gets NMPA Approval for Two Clinical Studies on Cancer Therapies

Fineline Cube Apr 24, 2023

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced receiving approval...

Company

YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials

Fineline Cube Apr 24, 2023

YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its...

Company

LianBio Appoints Pascal Qian as COO in Anticipation of Mavacamten Market Launch

Fineline Cube Apr 23, 2023

China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General...

Company Deals

Suzhou Basecare Medical and Qitan Tech Partner to Advance Nanopore Sequencing in PGT

Fineline Cube Apr 23, 2023

Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based in vitro fertilization (IVF) specialist, has...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Pyrotinib Gains NMPA Approval for HER2+ Breast Cancer Treatment

Fineline Cube Apr 23, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced receiving another indication...

Company Drug

Evopoint Biosciences Gets CDE Approval for Phase I/II Study of XNW27011 ADC

Fineline Cube Apr 23, 2023

Suzhou Evopoint Biosciences Co., Ltd., a China-based pharmaceutical company, has announced receiving approval from the...

Hospital Policy / Regulatory

China’s NHC Advances Enhanced Recovery After Surgery (ERAS) Protocols Nationwide

Fineline Cube Apr 23, 2023

The National Health Commission (NHC) has released a notification with the goal of promoting enhanced...

Company Drug

ChengDu ShengNuo Biotech Secures NMPA Approval for Generic Firazyr Equivalent

Fineline Cube Apr 23, 2023

ChengDu ShengNuo Biotech Co., Ltd (SHA: 688117), a China-based polypeptide specialist, has announced that it...

Company Deals

CanSino Biotechnology Leads RMB 500 Million Private Equity Fund for Vaccine Investments

Fineline Cube Apr 23, 2023

China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced plans to invest RMB 140...

Posts pagination

1 … 584 585 586 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.